Q4 2025 Danaher Corp Earnings Call Transcript
Key Points
- Danaher Corp (DHR) delivered a strong finish to 2025 with better-than-expected performance across its portfolio.
- The bioprocessing business showed continued strength, with high-single-digit growth in consumables and mid-single-digit growth in equipment.
- The company launched several innovative products, including Cytiva's new bioreactor formats and Protein A resins, and SCIEX's ZenoTOF 8600 mass spectrometer.
- Danaher Corp (DHR) generated $5.3 billion of free cash flow, marking the 34th consecutive year with a free cash flow to net income conversion ratio exceeding 100%.
- The Diagnostics segment saw mid-single-digit growth outside of China, with notable performance from Leica Biosystems and Beckman Coulter Diagnostics.
- Core revenue in discovery and medical declined at a high-single-digit rate due to difficult prior year comparisons and funding constraints in academic research.
- Academic and government demand remained muted, particularly in the US and China, affecting the Life Sciences segment.
- The fourth-quarter adjusted gross profit margin and adjusted operating profit margin were both down 130 basis points year-over-year.
- China's core revenue declined slightly, impacting overall growth in high-growth markets.
- The company faces ongoing macroeconomic pressures and policy headwinds, particularly affecting the Life Sciences segment.
Good day, everyone. My name is Nikki, and I will be your conference facilitator this morning. At this time, I would like to welcome everyone to Danaher Corporation's fourth-quarter 2025 earnings results conference Call. (Operator Instructions)
I will now turn the call over to Mr. John Bedford, Vice President of Investor Relations. Mr. Bedford, you may begin your conference.
Good morning, everyone, and thanks for joining us on the call. With us today are Rainer Blair, our President and Chief Executive Officer; and Matt McGrew, our Executive Vice President and Chief Financial Officer.
I'd like to point out that our earnings release, the slide presentation supplementing today's call, the reconciliations and other information required by SEC Regulation G, and the note containing details of historical and anticipated future financial performance, are all available on the Investors section of our website, www.danaher.com,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
